Benitec Biopharma (BNTC) Projected to Post Earnings on Monday

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) will likely be releasing its earnings data on Monday, February 10th. Analysts expect Benitec Biopharma to post earnings of ($0.55) per share for the quarter.

Benitec Biopharma Stock Performance

Shares of Benitec Biopharma stock traded down $0.27 on Thursday, hitting $11.48. 23,194 shares of the company traded hands, compared to its average volume of 33,108. The stock's 50 day moving average price is $11.34 and its 200-day moving average price is $10.17. Benitec Biopharma has a 52 week low of $2.70 and a 52 week high of $13.29.

Insider Activity

In other Benitec Biopharma news, Director Suvretta Capital Management, L acquired 27,502 shares of the firm's stock in a transaction dated Monday, December 23rd. The stock was purchased at an average price of $10.98 per share, for a total transaction of $301,971.96. Following the acquisition, the director now owns 7,981,725 shares in the company, valued at approximately $87,639,340.50. This trade represents a 0.35 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.30% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on BNTC shares. Baird R W upgraded Benitec Biopharma to a "strong-buy" rating in a report on Thursday, December 12th. Piper Sandler reaffirmed an "overweight" rating on shares of Benitec Biopharma in a research note on Friday, October 18th. Oppenheimer began coverage on shares of Benitec Biopharma in a research report on Wednesday, October 16th. They set an "outperform" rating and a $35.00 target price on the stock. JMP Securities upped their price target on shares of Benitec Biopharma from $16.00 to $18.00 and gave the stock a "market outperform" rating in a research report on Monday, October 14th. Finally, HC Wainwright began coverage on shares of Benitec Biopharma in a research note on Monday, December 16th. They set a "buy" rating and a $28.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $24.43.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.